Neuroblastoma Working Group

Ομάδα Εργασίας Νευροβλαστώματος της ΕΕΠΑΟ

Στην Ομάδα Νευροβλαστώματος συμμετέχουν όλα τα Τμήματα Παιδιατρικής Αιματολογίας-Ογκολογίας της χώρας με τους ακόλουθους εκπροσώπους:

ΣΥΝΤΟΝΙΣΤΗΣ

Vassilios Papadakis

ΕΚΠΡΟΣΩΠΟΙ ΤΜΗΜΑΤΩΝ ΜΕ ΔΙΚΑΙΩΜΑ ΨΗΦΟΥ

ΟΤΑΚ

D. Doganis

ΠΟΑιΜ

N. Roka

ΤΑΟ

V. Papadakis

ΠΕΠΑΓΝΗ

N. Kantzilakis

ΙΠΠΟΚΡΑΤΕΙΟ

Ε. Papakonstantinou

ΜΗΤΕΡΑ

E. Dana

ΑΧΕΠΑ

E. Chatzipantelis

ΜΕΛΗ ΟΜΑΔΑΣ

M. Servitzoglou, E. Magou, A. Vlachou, A. Kontogiorgou, V. Tzotzola, I. Pelagiadis, L. Damianidou, M. Ioannidou, E. Kosmidi, S. Polychronopoulou, A. Kattamis, E Steikaki, K. Stefanaki, A. Michael, G. Paterakis, A. Alexopoulou, M. Kourti, P. Panagopoulou, M. Moschovi, V. Lyra, V. Prassopoulos, N. Christopoulos, I. Georgopoulos, A. Paisiou, E. Gousetis

Ακριβές Πλαίσιο του Επιστημονικού Αντικειμένου της Ομάδας:

Study, proper treatment and registration of patients with peripheral neurogenic tumors (Neuroblastoma). Participation in International treatment protocols through the SIOPEN organization. National registration and implementation of harmonized treatments (immuno-chemotherapy and MIBG treatment based on the VERITAS protocol). Development of National research proposals, such as the evaluation of minimal residual disease study in the bone marrow with next-generation flow cytometry.

Δραστηριότητα/εξελίξεις, πρωτοβουλίες/ερευνητικές προτάσεις και πρωτόκολλα:

1. SIOPEN HR-NBL-1 High Risk Treatment Protocol:
a. Analysis of the outcome of Patients officially enrolled in the Protocol nationally
b. Complete follow-up of patients officially enrolled in it
2. LINES Low and Intermediate Risk Treatment Protocol:
a. Analysis of the outcome of patients officially enrolled in the protocol nationally
b. Complete follow-up of patients officially enrolled in it
c. Closure of the LINES Protocol
3. SIOPEN HR-NBL-2 High Risk treatment protocol: Initiation of protocol, registration of patients from all centers in Greece, follow-up, information on developments and updates of the Protocol.
4. National Registry and analysis of patient outcomes with:
a. CNS involvement
b. Use of Dinutuximab beta targeting antibody
c. Use of immuno-chemotherapy
d. Treatment according to VERITAS Protocol, use of Tandem Transplants/ MIBG Rx
5. Participation in the European BIOPORTAL program